2 days Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new position in shares of REGENXBIO Inc. ( NASDAQ:RGNX – Free Report ) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 7,000 shares of the biotechnology company’s stock, valued at approximately $54,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC increased its stake in shares of REGENXBIO by 141.3% in the third quarter.
Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 67,948 shares in the last quarter. Assenagon Asset Management S.A.
lifted its holdings in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.
A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after buying an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its position in REGENXBIO by 602.
9% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 17,533 shares during the last quarter. FMR LLC increased its stake in shares of REGENXBIO by 166.
8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the period. Finally, Stifel Financial Corp raised its position in shares of REGENXBIO by 13.
3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after acquiring an additional 17,563 shares during the last quarter. Institutional investors and hedge funds own 88.
08% of the company’s stock. Analyst Ratings Changes RGNX has been the topic of several recent research reports. The Goldman Sachs Group cut REGENXBIO from a “buy” rating to a “neutral” rating and decreased their price target for the company from $38.
00 to $14.00 in a report on Tuesday, February 11th. Leerink Partners set a $24.
00 target price on shares of REGENXBIO in a report on Tuesday, March 18th. HC Wainwright cut their price target on REGENXBIO from $36.00 to $34.
00 and set a “buy” rating on the stock in a research note on Monday, March 17th. Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.
00 price target on the stock. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th.
Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.78.
REGENXBIO Stock Up 8.9 % Shares of RGNX stock opened at $5.89 on Friday.
The firm has a fifty day moving average of $7.00 and a 200-day moving average of $8.29.
The company has a market capitalization of $295.01 million, a price-to-earnings ratio of -1.17 and a beta of 1.
26. REGENXBIO Inc. has a 12-month low of $5.
04 and a 12-month high of $19.38. REGENXBIO ( NASDAQ:RGNX – Get Free Report ) last announced its earnings results on Thursday, March 13th.
The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.
26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.
19%. The business had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.
70 million. On average, equities analysts expect that REGENXBIO Inc. will post -4.
84 EPS for the current year. About REGENXBIO ( Free Report ) REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. Further Reading Five stocks we like better than REGENXBIO What is a buyback in stocks? A comprehensive guide for investors JPMorgan is a Buy, if You Can Handle The Volatility Using the MarketBeat Dividend Yield Calculator United States Steel’s Crash: An Unmissable Buying Opportunity 3 Ways To Invest In Coffee, Other Than Drinking It Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter .
.
